TLSA Tiziana Life Sciences plc

7.7
-0.3  -4%
Previous Close 8
Open 7.99
Price To Book 192.5
Market Cap 105077134
Shares 13,646,381
Volume 4,434
Short Ratio
Av. Daily Volume 3,589

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial initiation announced November 28, 2018.
Foralumab
NASH (healthy human volunteers)
Phase 2a top-line data due 3Q 2019.
Milciclib
Hepatocellular carcinoma (HCC)
Phase 2b trial to be initiated in 2019.
Milciclib and Sorafenib (Nexavar)
Hepatocellular carcinoma (HCC)